Central Serous Chorioretinopathy
"Central Serous Chorioretinopathy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A visual impairment characterized by the accumulation of fluid under the retina through a defect in the retinal pigment epithelium.
Descriptor ID |
D056833
|
MeSH Number(s) |
C11.768.175
|
Concept/Terms |
Central Serous Chorioretinopathy- Central Serous Chorioretinopathy
- Central Serous Chorioretinopathies
- Chorioretinopathies, Central Serous
- Chorioretinopathy, Central Serous
- Serous Chorioretinopathies, Central
- Serous Chorioretinopathy, Central
- Central Serous Retinopathy
- Central Serous Retinopathies
- Retinopathies, Central Serous
- Retinopathy, Central Serous
- Serous Retinopathies, Central
- Serous Retinopathy, Central
|
Below are MeSH descriptors whose meaning is more general than "Central Serous Chorioretinopathy".
Below are MeSH descriptors whose meaning is more specific than "Central Serous Chorioretinopathy".
This graph shows the total number of publications written about "Central Serous Chorioretinopathy" by people in this website by year, and whether "Central Serous Chorioretinopathy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2011 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2018 | 1 | 0 | 1 |
2021 | 0 | 1 | 1 |
2022 | 1 | 1 | 2 |
2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Serous Chorioretinopathy" by people in Profiles.
-
Update on the Management of Central Serous Chorioretinopathy. Int Ophthalmol Clin. 2024 Jan 01; 64(1):179-193.
-
Clinical impact of the worldwide shortage of verteporfin (Visudyne?) on ophthalmic care. Acta Ophthalmol. 2022 Nov; 100(7):e1522-e1532.
-
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022 02; 23(2):248-258.
-
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815.
-
Central Serous Chorioretinopathy Associated With Fingolimod Treatment. J Neuroophthalmol. 2018 09; 38(3):337-338.
-
Subthreshold Micropulse Laser Photocoagulation in the Management of Central Serous Chorioretinopathy. Int Ophthalmol Clin. 2016; 56(4):165-74.
-
Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab. Eur J Ophthalmol. 2011 Jul-Aug; 21(4):506-8.